**Senior Scientist in Personalized Oncology**
We are seeking a highly motivated and experienced scientist to join our team in the Division of Personalized Medical Oncology, focusing on novel cancer-promoting mechanisms, therapy resistance, and functional characterization of atypical mutations.
**Job Description**
* Conceptualize and develop own projects in personalized oncology
* Develop patient-derived model system platform to predict response and overcome resistance
* Supervise Postdocs, PhD, undergraduate students, and technical staff
* Project planning and management
* Independent application for research grants
* Gene technology project manager
* Writing of research papers
* Presentation of results in the academic community
**Requirements**
* Master's degree and PhD, MD, or MD-PhD with a proven track record of research excellence
* Strong expertise in cancer biology, precision oncology, patient-derived model systems, cloning strategies, pre-clinical tumor models, protein biochemistry, molecular biology, single-cell technologies, and digital oncology
* Bioinformatic proficiency and gene technology expertise according to §28 GenTSV
* Excellent social skills, leadership, and communication skills
* Proficiency in German and English
**What We Offer**
* Excellent framework conditions, including state-of-the-art equipment and international networking opportunities
* 30 days of vacation per year
* Possibility of part-time work
* Sustainable travel to work with subsidized Germany job ticket
* Access to the DKFZ International Postdoc Program and DKFZ Career Service
* Remuneration according to TV-L, including occupational pension plan and capital-forming payments
* Flexible working hours
* Family-friendly working environment
* Corporate Health Management Program
**About the Company**
The DKFZ-Hector Cancer Institute is a partnership between the German Cancer Research Center, the University Hospital Mannheim, and the Medical Faculty Mannheim of Heidelberg University, with generous support from the Hector Foundation II. Our division focuses on the identification of novel cancer-promoting mechanisms, tackling of therapy resistance, and functional characterization of atypical mutations in major cancer-driving oncogenes.